Genetics, risk factors and COVID-19
- Funded by UK Research and Innovation (UKRI)
- Total publications:0 publications
Grant number: C19-IUC-385
Grant search
Key facts
Disease
COVID-19Funder
UK Research and Innovation (UKRI)Principal Investigator
Dr. Stephen BurgessResearch Location
United KingdomLead Research Institution
MRC Biostatistics UnitResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementation
Research Subcategory
Prophylactic use of treatments
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Randomized Controlled Trial
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
How can we answer questions of causation ("what if?" questions) when we can't perform experiments directly? In the case of COVID-19, a typical causal question would look like this: what would happen if we prescribed people anti-inflammatory medications? Would it improve outcomes? While we can answer these questions definitively by performing a randomized trial, this approach is slow. With this outbreak, time is of the essence and there are many potential treatments to evaluate. Instead of performing the randomization ourselves, our approach is to exploit a randomization that nature has provided for us in genetics.